Stock Market Update - November 14, 2025
Today's stock market saw some significant movers. Here's a breakdown of 5 stocks that caught our attention:
1. PTN - Palatin Technologies, Inc.
Price: $10.415 | Change: +2256.33% ($9.973)
PTN saw an astonishing 2256.33% gain in mid-November 2025, largely thanks to a dramatic financial turnaround. The biopharmaceutical company reported impressive fiscal first-quarter 2026 results, swinging to a $4.7 million net income from a $7.8 million loss the previous year. This was fueled by a significant increase in collaboration and license revenue, reaching $8.8 million, primarily from a research agreement with Boehringer Ingelheim for retinal diseases.
Further boosting confidence, Palatin completed a successful public offering, raising $18.2 million, which also helped them regain compliance for trading on the NYSE American. The funds from this offering are earmarked to advance their obesity program, which includes moving their oral small molecule PL7737 towards clinical trials and securing Orphan Drug Designation for a related condition. This confluence of a strong financial recovery and clear strategic advancements appears to have captivated investor attention.
2. CDTX - Cidara Therapeutics, Inc.
Price: $217.71 | Change: +105.41% ($111.72)
CDTX soared over 105% recently! This impressive jump for Cidara Therapeutics, Inc. happened because pharmaceutical giant Merck & Co. Inc. announced a definitive agreement to acquire Cidara. Merck plans an all-cash deal worth approximately $9.2 billion, offering $221.50 per share – a substantial 109% premium over Cidara's closing price before the news broke.
The main driver behind Merck's interest is Cidara's promising lead drug candidate, CD388. This novel long-acting antiviral is designed to prevent influenza A and B and is currently in late-stage clinical trials, having also received a special "Breakthrough Therapy" designation from the FDA. For Merck, this acquisition strategically diversifies its respiratory drug pipeline, especially as it looks to navigate upcoming patent expirations for its blockbuster cancer drug Keytruda.
3. CYPH - Cypherpunk Technologies Inc.
Price: $2.75 | Change: +56.25% ($0.99)
CYPH surged an impressive 56.25%, driven by a dramatic strategic pivot into the digital asset space. Formerly known as Leap Therapeutics, the company rebranded to Cypherpunk Technologies Inc. and shifted its entire focus from biopharmaceuticals to accumulating Zcash (ZEC) as its main digital treasury asset. This bold move, which also included key leadership appointments like Will McEvoy from Winklevoss Capital as Chief Investment Officer, was supported by a $58.88 million private placement led by Winklevoss Capital. A substantial $50 million from these proceeds was immediately deployed to acquire over 200,000 Zcash tokens.
What's particularly interesting is that shortly after their acquisition, Zcash defied a broader cryptocurrency market downturn, gaining 16% in just 24 hours. This meant Cypherpunk's new ZEC holdings saw a significant unrealized gain right out of the gate. This quick win, combined with the company's new identity and exposure to privacy-focused digital assets, generated considerable investor excitement and high trading volumes.
4. CYCU - Cycurion, Inc. Common Stock
Price: $6.32 | Change: +51.20% ($2.14)
CYCU just surged by an impressive 51.20% in mid-November 2025, thanks to a powerful combination of positive company news. The cybersecurity firm released an optimistic third-quarter earnings report, highlighting a robust contract backlog exceeding $80 million and offering confident future revenue guidance.
Adding to this momentum, Cycurion successfully regained compliance with Nasdaq's listing requirements, alleviating investor concerns about its stock exchange status. Furthermore, recent multi-million dollar contract wins—including a significant deal to modernize a U.S. federal emergency warning network and a separate data modernization project—bolstered investor confidence, signaling a healthy pipeline of future business. This collective good news painted a promising picture for the company's trajectory.
5. WSHP - Wasatch Pharmaceutical, Inc.
Price: $30.21 | Change: +50.90% ($10.19)
WSHP just experienced an impressive 50.90% gain. This significant surge, seen around November 15, 2025, is attributed to the Nasdaq debut of WeShop Holdings Limited, a new social-commerce platform. It's important to note that this movement is not related to Wasatch Pharmaceutical, Inc., which previously shared the same ticker; the excitement is squarely around WeShop's market entry.
WeShop is making waves with its unique "ShareBack™ Rewards Plan," allowing users to earn ownership in the company by shopping and making referrals. This model, which has seen over 50% of its shares committed to a trust for shoppers, aims to usher in a "new retail revolution" by blending e-commerce, social interaction, and user ownership, making public market access more inclusive.
This analysis was generated using AI and real-time stock data. Always do your own research before making investment decisions.